Cyclacel Pharmaceuti (CYCC)

$0.24 -0.01 (-4.80%)
Market Cap 5.61M
Revenue (ttm) 40,000.00
Net Income (ttm) -11.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28,025.00%
Debt to Equity Ratio 0.00
Volume 2,594,600
Avg Vol 1,955,482
Day's Range N/A - N/A
Shares Out 23.76M
Stochastic %K 11%
Beta 0.03
Analysts Strong Buy
Price Target $1.00

Company Profile

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.

Industry: Biotechnology
Sector: Healthcare
Phone: 60 9 08517 7330
Address:
Level 10, Tower 11 Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
CarlosAC
CarlosAC Jul. 7 at 12:04 AM
$CYCC RS in May and now another RS in July? 🗑️
0 · Reply
slick3333
slick3333 Jul. 4 at 12:29 AM
$CYCC expect another few quicks dumps down to less than a dollar I say by end of next week post reverse split
0 · Reply
Mey636363
Mey636363 Jul. 3 at 1:59 PM
$CYCC run away it's falling
0 · Reply
PaulLaurent
PaulLaurent Jul. 3 at 9:38 AM
🔄 Oversold Small Caps Update 📉🧪 $CGBS $OST $TDTH $CYCC with upcoming RS $GTI
1 · Reply
Mey636363
Mey636363 Jul. 3 at 8:26 AM
$CYCC 🗑️🗑️🗑️🗑️
0 · Reply
PaulLaurent
PaulLaurent Jul. 2 at 7:29 PM
🔄 Oversold Small Caps Update 📉🧪 $DFLI $BTOG $ATCH $IXHL $CYCC
1 · Reply
urgetosurge
urgetosurge Jul. 2 at 4:51 PM
$CYCC trashola crapola..
0 · Reply
GAO2
GAO2 Jul. 2 at 4:14 PM
$CYCC Reverse split on July 7th, 15 shares for 1. Expected price after the split to range from $4.5 to $4.24.
1 · Reply
firedupinvestors
firedupinvestors Jul. 2 at 1:53 PM
$CYCC dunb dumb me.
0 · Reply
firedupinvestors
firedupinvestors Jul. 2 at 1:43 PM
$CYCC bought at .38. should have known better. Cutting my losses. Im out.
0 · Reply
Latest News on CYCC
Cyclacel Pharmaceuticals Announces Stock Split

Jul 2, 2025, 9:00 AM EDT - 4 days ago

Cyclacel Pharmaceuticals Announces Stock Split

CYCCP

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Jun 20, 2025, 4:30 PM EDT - 16 days ago

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCCP

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Jun 3, 2025, 4:15 PM EDT - 4 weeks ago

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CYCCP

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 15, 2025, 12:50 AM EDT - 7 weeks ago

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCCP

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

May 7, 2025, 9:00 AM EDT - 2 months ago

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCCP

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

May 6, 2025, 6:00 AM EDT - 2 months ago

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.

CYCCP

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

Apr 2, 2025, 4:05 PM EDT - 3 months ago

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Mar 24, 2025, 7:30 AM EDT - 3 months ago

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

CYCCP

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

Feb 27, 2025, 1:38 PM EST - 4 months ago

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

CYCCP

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Jan 3, 2025, 9:01 AM EST - 6 months ago

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

CYCCP

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Dec 5, 2024, 4:05 PM EST - 7 months ago

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

CYCCP

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 14, 2024, 4:15 PM EST - 8 months ago

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Nov 13, 2024, 12:22 PM EST - 8 months ago

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Nov 12, 2024, 4:45 PM EST - 8 months ago

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Oct 24, 2024, 9:15 AM EDT - 9 months ago

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

CYCCP

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 23, 2024, 9:15 AM EDT - 9 months ago

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Oct 9, 2024, 9:15 AM EDT - 9 months ago

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Sep 25, 2024, 9:15 AM EDT - 10 months ago

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

CYCCP

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:15 AM EDT - 10 months ago

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

CYCCP

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

Sep 3, 2024, 9:15 AM EDT - 10 months ago

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:18 PM EDT - 11 months ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

Aug 7, 2024, 9:15 AM EDT - 11 months ago

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

CYCCP

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Jun 26, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

CYCCP

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:08 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

May 8, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

CYCCP

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

May 2, 2024, 4:30 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

CYCCP

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CYCCP

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Apr 1, 2024, 9:15 AM EDT - 1 year ago

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 6:09 PM EDT - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Mar 13, 2024, 4:05 PM EDT - 1 year ago

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

CYCCP

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Mar 7, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

CYCCP

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Mar 6, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

CYCCP

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Feb 20, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

CYCCP

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Jan 30, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

CYCCP

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jan 8, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

CYCCP

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Jan 2, 2024, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

CYCCP

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Dec 22, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

CYCCP

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Dec 18, 2023, 9:00 AM EST - 1 year ago

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

CYCCP

Cyclacel Pharmaceuticals Announces Reverse Stock Split

Dec 12, 2023, 4:05 PM EST - 1 year ago

Cyclacel Pharmaceuticals Announces Reverse Stock Split

CYCCP

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

Nov 30, 2023, 9:15 AM EST - 1 year ago

Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC

CYCCP

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

Nov 28, 2023, 5:15 PM EST - 1 year ago

Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q

CYCCP

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:32 PM EST - 1 year ago

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

Nov 7, 2023, 9:15 AM EST - 1 year ago

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

CYCCP

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

Aug 3, 2023, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results

CYCCP

Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript

May 11, 2023, 7:59 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript

CYCCP

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

CYCCP

Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

May 4, 2023, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

CYCCP

Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit

May 3, 2023, 9:15 AM EDT - 2 years ago

Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit

CYCCP

CarlosAC
CarlosAC Jul. 7 at 12:04 AM
$CYCC RS in May and now another RS in July? 🗑️
0 · Reply
slick3333
slick3333 Jul. 4 at 12:29 AM
$CYCC expect another few quicks dumps down to less than a dollar I say by end of next week post reverse split
0 · Reply
Mey636363
Mey636363 Jul. 3 at 1:59 PM
$CYCC run away it's falling
0 · Reply
PaulLaurent
PaulLaurent Jul. 3 at 9:38 AM
🔄 Oversold Small Caps Update 📉🧪 $CGBS $OST $TDTH $CYCC with upcoming RS $GTI
1 · Reply
Mey636363
Mey636363 Jul. 3 at 8:26 AM
$CYCC 🗑️🗑️🗑️🗑️
0 · Reply
PaulLaurent
PaulLaurent Jul. 2 at 7:29 PM
🔄 Oversold Small Caps Update 📉🧪 $DFLI $BTOG $ATCH $IXHL $CYCC
1 · Reply
urgetosurge
urgetosurge Jul. 2 at 4:51 PM
$CYCC trashola crapola..
0 · Reply
GAO2
GAO2 Jul. 2 at 4:14 PM
$CYCC Reverse split on July 7th, 15 shares for 1. Expected price after the split to range from $4.5 to $4.24.
1 · Reply
firedupinvestors
firedupinvestors Jul. 2 at 1:53 PM
$CYCC dunb dumb me.
0 · Reply
firedupinvestors
firedupinvestors Jul. 2 at 1:43 PM
$CYCC bought at .38. should have known better. Cutting my losses. Im out.
0 · Reply
Mey636363
Mey636363 Jul. 2 at 1:34 PM
$CYCC 🗑️
0 · Reply
Mey636363
Mey636363 Jul. 2 at 1:34 PM
$CYCC 💩💩💩💩💩💩💩💩💩💩💩💩💩
0 · Reply
urgetosurge
urgetosurge Jul. 2 at 1:29 PM
$CYCC another pos.
0 · Reply
aaron03
aaron03 Jul. 2 at 1:25 PM
$CYCC How many effing times does this stupid ass company have to do a reverse split? This must be a record. Talk about a Ponzi scheme
2 · Reply
gretaslaps
gretaslaps Jul. 2 at 1:00 PM
$CYCC RSSSSSSSSSS
0 · Reply
Mey636363
Mey636363 Jul. 2 at 9:56 AM
$CYCC 💩💩💩💩💩💩💩
0 · Reply
Mey636363
Mey636363 Jul. 2 at 9:56 AM
$CYCC 💩💩💩💩💩💩💩💩💩
0 · Reply
Mey636363
Mey636363 Jul. 2 at 8:54 AM
$CYCC 💩💩💩💩💩💩💩💩💩💩💩
0 · Reply
Mey636363
Mey636363 Jul. 2 at 8:51 AM
$CYCC 💩💩💩💩💩💩💩💩💩
0 · Reply
Oliver420
Oliver420 Jun. 30 at 3:19 PM
$CYCC down the pooper
0 · Reply
stockanalysis_
stockanalysis_ Jun. 28 at 3:33 PM
Most Shorted Stocks: $RAPT $HSDT $CYCC $FLWS $ATCH View the entire list here: https://stockanalysis.com/list/most-shorted-stocks/?ref=saveontrading
2 · Reply
urgetosurge
urgetosurge Jun. 27 at 4:28 PM
$CYCC news and she runs hard.
0 · Reply